Blood tests for Alzheimer's are now FDA-cleared for screening cognitive impairment, but they do not yet replace PET scans or spinal taps in standard diagnostic care. Two new blood biomarker tests—Lumipulse G pTau217/Aβ1-42 and Roche Elecsys pTau181—detect the brain proteins linked to Alzheimer's pathology and can identify who needs further testing. These tests work as a practical first step, especially in primary-care settings, but they sit alongside traditional imaging and cerebrospinal-fluid testing rather than replacing them entirely.
For someone with memory concerns, a blood test offers a less invasive entry point. It can rule out Alzheimer's pathology with high confidence or flag who should proceed to imaging or a lumbar puncture. The key question is not whether blood tests are "good enough"—they often are—but how they fit into the diagnostic sequence.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What's Approved and When
- How Accurate Are These Tests?
- When Blood Tests Are Used Versus PET and CSF
- Limitations and Ongoing Roles of Other Tests
- What to Do If You Have Memory Concerns
- Frequently Asked Questions
What's Approved and When
Lumipulse G pTau217/Aβ1-42 received FDA clearance in May 2025 for diagnosing amyloid pathology in symptomatic adults 55 and older. The approval applies only to people with cognitive symptoms; it is not for asymptomatic screening. A few months later, Roche's Elecsys pTau181 won FDA approval in October 2025 as a rule-out triage tool, with a 97.9% negative-predictive value—meaning it reliably identifies people without Alzheimer's pathology.
The distinction matters. Lumipulse is marketed as a diagnostic aid for symptomatic individuals; Elecsys is specifically positioned for primary-care triage to sort out who genuinely needs further investigation. Neither test is positioned as a standalone replacement for imaging or lumbar puncture.
How Accurate Are These Tests?
Plasma pTau217/Aβ1-42 achieves 91.7% concordance with amyloid-PET imaging when positive and 97.3% when negative—meaning when a blood test says amyloid pathology is present, imaging confirms it roughly 9 out of 10 times. When the blood test is negative, imaging typically agrees.
For phospho-tau variants, sensitivity ranges from 82–83% and specificity from 83–86%, with area-under-curve values of 0.95–0.97 for detecting both amyloid and tau pathology. Blood pTau217 performs comparably to cerebrospinal fluid (CSF) pTau217 for detecting amyloid, meaning a blood draw can often substitute for a lumbar puncture as a biomarker screen. The underlying technology—single-molecule-array (Simoa)—detects these proteins at extremely low concentrations, which is why accuracy rivals invasive testing.
When Blood Tests Are Used Versus PET and CSF
Blood biomarkers are now approved for screening and triage of symptomatic cognitive impairment to identify amyloid and tau pathology; PET imaging remains the gold standard for visual confirmation, and CSF testing is still used when detailed multianalyte assessment or research enrollment is required. In a typical pathway, someone with memory concerns might start with a blood test at a primary-care visit or memory clinic. If the result is negative, further investigation may not be needed.
If positive, the next step is often imaging or referral to a neurologist. Blood tests are fastest and least invasive, making them ideal for initial triage. However, they do not show *where* in the brain pathology is located—which imaging does. They also do not measure the full CSF protein profile, which can be diagnostically important in atypical presentations or in clinical trials.
Limitations and Ongoing Roles of Other Tests
A central limitation: a positive blood test indicates the *presence* of Alzheimer's pathology but does not predict whether symptoms will worsen, stabilize, or improve. Biomarker positivity alone is not a clinical diagnosis of Alzheimer's disease—many cognitively normal older adults have amyloid or tau without obvious impairment. Blood tests also cannot distinguish Alzheimer's from other dementias (Lewy body disease, frontotemporal dementia, vascular disease), which may require imaging or specialist assessment.
Lumbar puncture remains safe, with an adverse-event rate of 2.6% for mild post-LP headache and no major complications in 1,089 memory-clinic patients. For complex cases or research enrollment, a spinal tap may still be preferred because it provides multiple protein measurements simultaneously. Multimarker blood tests are in development, but CSF analysis remains the more comprehensive tool when a full biomarker profile is needed.
What to Do If You Have Memory Concerns
Asking your doctor about blood biomarker testing is reasonable if memory issues arise. These tests are increasingly available at memory clinics, neurology practices, and larger primary-care centers. A negative result can provide reassurance and may reduce the need for invasive testing; a positive result prompts discussion about imaging, monitoring, and possibly disease-modifying medications (such as anti-amyloid monoclonal antibodies) if appropriate for your age and stage.
Cost and insurance coverage vary. Some tests are covered by Medicare; others require out-of-pocket payment or clinical-trial enrollment. Ask your doctor whether the blood test is available through their facility and what the timeline for results is.
Frequently Asked Questions
Does a negative blood test mean I won't develop Alzheimer's?
No. A negative test suggests no current amyloid or tau pathology, but some cognitively normal people have pathology without symptoms or cognitive decline. Your doctor can discuss what a negative result means for your individual monitoring plan.
Can I get a blood test if I'm under 55 or don't have symptoms yet?
Current FDA-approved blood tests are cleared for symptomatic adults 55 and older. Off-label testing or clinical-trial enrollment may be available for younger individuals or asymptomatic screening; ask your doctor about eligibility.
If my blood test is positive, do I definitely have Alzheimer's?
A positive blood test indicates amyloid or tau pathology in your brain, but it does not diagnose Alzheimer's disease or predict symptoms. Imaging and clinical evaluation are usually needed to confirm diagnosis and determine next steps.
